Home › Calculator › CHRS Dividend Calculator 2026
CHRS Dividend DRIP Calculator 2026
161.29% YieldHealthcareCoherus Oncology, Inc. · NASDAQ
Price: $1.24 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When CHRS pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your CHRS snowball 📈
$10,000 in CHRS → $73734882393994.27M in 10 years · $6,140,855,436,767,626,000.00/month
About Coherus Oncology, Inc. (CHRS) — Dividend Analysis 2026
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
Compare CHRS with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full CHRS DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CHRS position with:
🌍 CHRS Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold CHRS.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 161.29% | 158.49% | $16,129 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 137.10% | 134.30% | $13,710 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 129.03% | 126.23% | $12,903 / yr |
| 🇬🇧 UK ISA | 0% | 161.29% | 158.49% | $16,129 / yr |
| 🇬🇧 UK Taxable | 8.75% | 147.18% | 144.38% | $14,718 / yr |
| 🇨🇦 TFSA | 0% | 161.29% | 158.49% | $16,129 / yr |
| 🇨🇦 CA Taxable | 25% | 120.97% | 118.17% | $12,097 / yr |
| 🇦🇺 Super (pension) | 15% | 137.10% | 134.30% | $13,710 / yr |
| 🇦🇺 AU Taxable | 30% | 112.90% | 110.10% | $11,290 / yr |
| 🇩🇪 DE Taxable | 26.375% | 118.75% | 115.95% | $11,875 / yr |
| 🇫🇷 FR Taxable | 30% | 112.90% | 110.10% | $11,290 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 CHRS Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 CHRS Dividend Payment Schedule
CHRS pays quarterly — 4 times per year. Next ex-div: TBD.
📊 CHRS vs Healthcare Benchmarks
How CHRS compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CHRS sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ CHRS Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-05 | 60,000 | $1.45 | $87.0K | ||
| A-Award | 2026-06-05 | 30,000 | — | — | ||
| A-Award | 2026-06-05 | 60,000 | $1.45 | $87.0K | ||
| A-Award | 2026-06-05 | 30,000 | — | — | ||
| A-Award | 2026-06-05 | 60,000 | $1.45 | $87.0K | ||
| A-Award | 2026-06-05 | 30,000 | — | — | ||
| A-Award | 2026-06-05 | 60,000 | $1.45 | $87.0K | ||
| A-Award | 2026-06-05 | 30,000 | — | — | ||
| A-Award | 2026-06-05 | 60,000 | $1.45 | $87.0K | ||
| A-Award | 2026-06-05 | 30,000 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where CHRS earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CHRS dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Coherus Oncology, Inc. (CHRS) is currently trading at $1.24, 93% below its 52-week high. The current dividend yield is 161.29% based on an annual payout of $2.00 per share.
CHRS (Coherus Oncology, Inc.) — 161.29% Dividend Yield Analysis
Coherus Oncology, Inc. (CHRS) is a healthcare stock currently trading at $1.24 with a dividend yield of 161.29%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (161.29%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.